In last trading session, Xilio Therapeutics Inc (NASDAQ:XLO) saw 59682.0 shares changing hands with its beta currently measuring -0.29. Company’s recent per share price level of $1.01 trading at $0.02 or 1.77% at ring of the bell on the day assigns it a market valuation of $44.39M. That closing price of XLO’s stock is at a discount of -91.09% from its 52-week high price of $1.93 and is indicating a premium of 51.49% from its 52-week low price of $0.49. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.19 million shares which gives us an average trading volume of 263.79K if we extend that period to 3-months.
For Xilio Therapeutics Inc (XLO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.33. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.24 in the current quarter.
Xilio Therapeutics Inc (NASDAQ:XLO) trade information
Upright in the green during last session for gaining 1.77%, in the last five days XLO remained trading in the green while hitting it’s week-highest on Tuesday, 11/26/24 when the stock touched $1.01 price level, adding 2.88% to its value on the day. Xilio Therapeutics Inc’s shares saw a change of 83.64% in year-to-date performance and have moved 7.31% in past 5-day. Xilio Therapeutics Inc (NASDAQ:XLO) showed a performance of 2.02% in past 30-days. Number of shares sold short was 41958.0 shares which calculate 0.1 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a rise of 85.57% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 7. It follows that stock’s current price would drop -593.07% in reaching the projected high whereas dropping to the targeted low would mean a loss of -593.07% for stock’s current value.
Xilio Therapeutics Inc (XLO) estimates and forecasts
Statistics highlight that Xilio Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 8.59% of value to its shares in past 6 months, showing an annual growth rate of 58.99% while that of industry is 17.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -44.91% during past 5 years.
Xilio Therapeutics Inc (NASDAQ:XLO)’s Major holders
Insiders are in possession of 40.92% of company’s total shares while institution are holding 33.50 percent of that, with stock having share float percentage of 56.71%. Investors also watch the number of corporate investors in a company very closely, which is 33.50% institutions for Xilio Therapeutics Inc that are currently holding shares of the company. BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC is the top institutional holder at XLO for having 3.79 million shares of worth $3.59 million. And as of 2024-06-30, it was holding 13.5618 of the company’s outstanding shares.
The second largest institutional holder is ROCK SPRINGS CAPITAL MANAGEMENT LP, which was holding about 3.0 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.7595 of outstanding shares, having a total worth of $2.85 million.
